Clinical trial · no report yet · Phase 2
NCT03768570
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
- NCT03768570 ↗
- Active, not recruiting
- Canadian Cancer Trials Group
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Bladder Cancer
- Interventions
- Durvalumab
- Arms
- Surveillance · No intervention
- Durvalumab · Active comparator
- Enrollment
- 82
- Primary outcomes
- Disease-free survival
- Sponsor
- Canadian Cancer Trials Group with AstraZeneca
- Start
- Oct 25, 2019
- Primary completion
- Oct 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03768570 · updated Jun 18, 2026